SG Americas Securities LLC Makes New Investment in Cabaletta Bio, Inc. (NASDAQ:CABA)

SG Americas Securities LLC purchased a new stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) during the third quarter, HoldingsChannel.com reports. The fund purchased 35,098 shares of the company’s stock, valued at approximately $166,000.

A number of other institutional investors have also recently made changes to their positions in the stock. EntryPoint Capital LLC bought a new position in Cabaletta Bio during the first quarter valued at approximately $147,000. Bayesian Capital Management LP purchased a new position in shares of Cabaletta Bio in the 1st quarter worth $191,000. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Cabaletta Bio in the first quarter worth $305,000. Blair William & Co. IL grew its holdings in shares of Cabaletta Bio by 47.3% in the first quarter. Blair William & Co. IL now owns 27,300 shares of the company’s stock worth $466,000 after acquiring an additional 8,762 shares during the period. Finally, California State Teachers Retirement System increased its position in Cabaletta Bio by 6.0% during the first quarter. California State Teachers Retirement System now owns 30,428 shares of the company’s stock valued at $519,000 after acquiring an additional 1,711 shares during the last quarter.

Cabaletta Bio Stock Performance

CABA opened at $3.86 on Friday. The stock has a market cap of $186.11 million, a price-to-earnings ratio of -2.26 and a beta of 2.39. The firm’s fifty day moving average is $4.66 and its 200 day moving average is $8.16. Cabaletta Bio, Inc. has a fifty-two week low of $3.47 and a fifty-two week high of $26.35.

Cabaletta Bio (NASDAQ:CABA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.01). On average, equities research analysts predict that Cabaletta Bio, Inc. will post -2.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. UBS Group started coverage on Cabaletta Bio in a research report on Thursday, October 10th. They issued a “buy” rating and a $10.00 target price on the stock. Evercore ISI dropped their price objective on shares of Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating on the stock in a report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Cabaletta Bio in a report on Tuesday, September 17th. Finally, Wells Fargo & Company dropped their price target on shares of Cabaletta Bio from $35.00 to $20.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, Cabaletta Bio has an average rating of “Buy” and an average price target of $28.10.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.